After the FDA approved AcelRx's Dsuvia for the management of acute pain in certified medically supervised healthcare settings, Ladenburg analyst Michael Higgins said data shows there are more than 100M patients with pain in medical institutions annually and about 40M with moderate-to-severe acute pain that receive opioids in the Emergency Department, giving the drug a "very large market opportunity." Adding that forecasting the rate of adoption of a novel drug to hospital formularies is difficult, Higgins left his prior revenue estimates unchanged following the approval news. He reiterates a Buy rating and $10 price target on AcelRx shares.